Search
Ertugliflozin
go.drugbank.com/drugs/DB11827ApprovedInvestigational[A31581] Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018.[L48621] … Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus.
Categories: Drugs Used in DiabetesSynonyms: 1,6-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-5-C-(hydroxymethyl)-β-L-idopyranose, β-L-Idopyranose, 1,6-anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-5-C-(hydroxymethyl)-Apraclonidine
go.drugbank.com/drugs/DB00964ApprovedInvestigationalApraclonidine, also known as iopidine, is a sympathomimetic used in glaucoma therapy. It is an alpha2-adrenergic agonist.
Categories: Sympathomimetics in Glaucoma TherapyOmega-3-carboxylic acids
go.drugbank.com/drugs/DB09568ApprovedWithdrawnThe omega-3 carboxylic acid (OM3-CA) is a new formulation of omega-3 fatty acids that present an enhanced bioavailability in the treatment of dyslipidemia. … The increased bioavailability is explained because OM3-CA is found in a form of polyunsaturated free fatty acids as opposed to other products whose form is as ethyl esters.
Misoprostol
go.drugbank.com/drugs/DB00929ApprovedInvestigational[A181586] Misoprostol was granted FDA approval on 27 December 1988.[L7616] … [L7616,L7619,A181589,A181583,A181697] The stimulation of prostaglandin receptors in the stomach reduces gastric acid secretion, while stimulating these receptors in the uterus and cervix can increase the
Categories: Prostaglandin E1 Analog, Prostaglandins E, SyntheticNitrous oxide
go.drugbank.com/drugs/DB06690ApprovedInvestigationalVet approvedAt room temperature, it is a colorless non-flammable gas, with a pleasant, slightly sweet odor and taste. It is used in surgery and dentistry for its anesthetic and analgesic effects. … It is known as "laughing gas" due to the euphoric effects of inhaling it, a property that has led to its recreational use as an inhalant drug.
Mixtures: Nitrous Oxide In OxygenProducts: N/AButalbital
go.drugbank.com/drugs/DB00241ApprovedIllicitButalbital, or 5-allyl-5-isobutylbarbituric acid, is a derivative of barbituric acid which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group. … [L10370] Butalbital‐containing analgesics can also produce a drug‐induced headache in addition to tolerance and dependence.
Mixtures: Vtol LQ, Alagesic LQSynonyms: 5-allyl-5-(2'-methyl-n-propyl) barbituric acidSacituzumab govitecan
go.drugbank.com/drugs/DB12893ApprovedInvestigational[A193653] Targeted chemotherapy through the application of antibody-conjugated agents (ADCs) is a recent advance in cancer treatment. … [A193671] One such ADC is sacituzumab govitecan, which combines a humanized anti-trophoblast cell-surface antigen 2 (TROP-2) antibody with the topoisomerase I inhibitor SN-38.
Insulin icodec
go.drugbank.com/drugs/DB16693ApprovedInvestigational[A264093] These modifications - which cause increased serum albumin binding and attenuated insulin receptor affinity - result in a mean half-life of approximately 196 hours, allowing for once-weekly administration … It is a re-engineered version of the ultra long-acting oral basal insulin OI338, with several modifications introduced to significantly extend the half-life.
Categories: Drugs Used in DiabetesVoclosporin
go.drugbank.com/drugs/DB11693ApprovedInvestigationalWithin 10 years of being diagnosed with SLE, 5-20% of those suffering from LN develop end-stage kidney disease, a fatal condition. … LN is a significant cause of renal failure, morbidity, and death in patients with SLE.